STLN — Starling Oncology, Inc.
—
Nasdaq ·
Health Care ·
Health Care Providers & Services ·
CIK 1799191 ·
Last close
$3.40
Market Cap
$346.51M
52W High
$7.13
52W Low
$2.32
ADV30
3,713,768
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 169,767,000 | 30,670,000 | -2,982,000 | -15,748,000 | 187,773,000 | 36,895,000 | 225,128,000 |
| Jun 2026 | 161,282,000 | 27,165,000 | -4,616,000 | -9,789,000 | 178,233,000 | 41,094,000 | 203,147,000 |
| Mar 2026 | 147,441,000 | 23,315,000 | -6,513,000 | -2,492,000 | 168,230,000 | 30,280,000 | 184,515,000 |
| Dec 2025 | 141,957,000 | 22,765,000 | -6,907,000 | -7,508,000 | 164,656,000 | 33,565,000 | 180,376,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$328,000
Investing CF
$-3,614,000
Financing CF
$14,088,000
CapEx
$-3,614,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.30
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,700,000
Inventory
$20,011,000
Receivables
$66,709,000
ST Investments
—
EBIT TTM
$-28,664,000
Pretax Income TTM
$-36,293,000
Interest Exp TTM
$7,629,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$620,446,976
EBITDA
$-14,410,000
Free Cash Flow
$29,539,624
Enterprise Value
$435,067,520
Total Cash
$36,895,000
Total Debt
$102,755,000
Shares Out
101,916,115
Trailing EPS
$-0.28
Book Value
$-0.37
ROE
—
ROA
-7.5%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 502,729,000 | -36,083,000 | -60,606,000 | 164,656,000 | 180,376,000 | -15,720,000 | -24,587,000 |
| Dec 2024 | 393,412,000 | -60,118,000 | -64,663,000 | 172,717,000 | 169,128,000 | 3,589,000 | -26,538,000 |
| Dec 2023 | 324,239,000 | -60,151,000 | -83,068,000 | 209,240,000 | 152,215,000 | 57,025,000 | -36,315,000 |
| Dec 2022 | 252,483,000 | -72,007,000 | 152,000 | 261,665,000 | 138,490,000 | 123,175,000 | -61,756,000 |
TTM Snapshot
Revenues TTM
$587,244,000
NetIncome TTM
$-36,293,000
OpCashFlow TTM
—
Assets (Latest)
$178,233,000
Forward EPS
—
Max Pain — expiry 2027-02-19
max pain strike: $4.00 · spot: $3.20 · call oi: 19,659 · put oi: 1,417
Expected Move to 2027-02-19:
±$1.00
(31.25%) —
implied range
$2.20 –
$4.20
· ATM straddle on $3.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VMD | VIEMED HEALTHCARE, INC. | $343.69M | $9.07 | — |
| YDES | YD Bio Ltd | $335.03M | $4.73 | — |
| CYH | COMMUNITY HEALTH SYSTEMS INC | $284.87M | $2.02 | — |
| DFPH | Starling Oncology, Inc. | $436.37M | $2.01 | — |
| MCTA | Charming Medical Ltd | $445.55M | $29.35 | — |
News headlines (Yahoo Finance, 1h cache)
Oncology Institute Q3 Earnings Call Highlights
2026-11-06 14:14 · Yahoo
Starling Oncology, Inc. (STLN) Reports Q3 Loss, Beats Revenue Estimates
2026-11-05 21:45 · Yahoo
Starling Oncology Reports Third Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
2026-11-05 21:06 · Yahoo
Starling Oncology Announces Third Quarter 2026 Earnings Release Date and Conference Call
2026-10-26 13:00 · Yahoo
Starling Oncology (STLN) Stock Gets Fair Value Boost On Capitated Revenue And Nexus Views
2026-10-15 23:22 · Yahoo
Starling Oncology to Participate in Wells Fargo Healthcare Conference
2026-08-24 13:00 · Yahoo
The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates
2026-08-06 23:10 · Yahoo
Geron (GERN) Reports Break-Even Earnings for Q3
2026-11-04 12:55 · Yahoo
Ultragenyx (RARE) Reports Q3 Loss, Lags Revenue Estimates
2026-11-03 21:50 · Yahoo
Starling Oncology Leadership Highlights Recent and Upcoming Industry Conference Participation
2026-10-01 20:14 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.